Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GlaxoSmithKline/Pozen Anticipate Mid-2007 Launch For Trexima Migraine Combo

This article was originally published in The Pink Sheet Daily

Executive Summary

Pozen is counting on safety data from two GSK Phase IIIb trials completed after the migraine therapy’s filing to satisfy FDA’s “approvable” letter.

You may also be interested in...



Pozen/GlaxoSmithKline’s Trexima Gets Second FDA Approvable Letter

Pozen plans to pursue additional toxicity studies suggested by FDA.

Pozen/GlaxoSmithKline’s Trexima Gets Second FDA Approvable Letter

Pozen plans to pursue additional toxicity studies suggested by FDA.

GSK/Pozen To Reformat Trexima Clinical Trial Data

The firm now expects a late-June user fee date for the migraine treatment.

Related Content

Topics

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel